Cite
Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer.
MLA
Lee, Hey Min, et al. “Epigenome Reprogramming through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, Sept. 2024. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-1166.
APA
Lee, H. M., Saw, A. K., Morris, V. K., Napolitano, S., Bristow, C., Srinivasan, S., Peoples, M., Sorokin, A., Kanikarla Marie, P., Schulz, J., Singh, A. K., Terranova, C., Coker, O., Jain, A., Kopetz, S., & Rai, K. (2024). Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-24-1166
Chicago
Lee, Hey Min, Ajay Kumar Saw, Van K Morris, Stefania Napolitano, Christopher Bristow, Sanjana Srinivasan, Michael Peoples, et al. 2024. “Epigenome Reprogramming through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, September. doi:10.1158/1078-0432.CCR-24-1166.